Jaqueline Duarte

Mrs. Jaqueline Duarte

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
IGIsabela Pereira Gomes
Isabela Pereira Gomes
JDJaqueline Duarte
Jaqueline Duarte
AMAna Luiza Chaves Maia
Ana Luiza Chaves Maia
Domenico RubelloDomenico Rubello
Domenico Rubello
DTDanyelle M. Townsend
Danyelle M. Townsend
ELElaine Amaral Leite
Elaine Amaral Leite
Conventional chemotherapy regimens have limitations due to serious adverse effects. Targeted drug delivery systems to reduce systemic toxicity are a powerful drug development platform. Encapsulation of antitumor drug(s) in thermosensitive nanocarriers is an emerging approach with a promise to improve uptake and increase therapeutic efficacy, as they can be activated by hyperthermia selectively at the tumor site. In this review, we focus on thermosensitive nanosystems associated with hyperthermia for the treatment of cancer, in preclinical and clinical use.

21 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JDJaqueline Duarte
Jaqueline Duarte
EGEliza Rocha Gomes
Eliza Rocha Gomes
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
ELElaine Amaral Leite
Elaine Amaral Leite
Doxorubicin (DOX) is a potent chemotherapeutic drug used as the first line in breast cancer treatment; however, cardiotoxicity is the main drawback of the therapy. Preclinical studies evidenced that the association of simvastatin (SIM) with DOX leads to a better prognosis with reduced side effects and deaths. In this work, a novel pH-sensitive liposomal formulation capable of co-encapsulating DOX and SIM at different molar ratios was investigated for its potential in breast tumor treatment. Studies on physicochemical characterization of the liposomal formulations were carried out. The cytotoxic effects of DOX, SIM, and their combinations at different molar ratios (1:1; 1:2 and 2:1), free or co-encapsulated into pH-sensitive liposomes, were evaluated against three human breast cancer cell lines (MDA-MB-231, MCF-7, and SK-BR-3). Experimental protocols included cell viability, combination index, nuclear morphological changes, and migration capacity. The formulations showed a mean diameter of less than 200 nm, with a polydispersity index lower than 0.3. The encapsulation content was ~100% and ~70% for DOX and SIM, respectively. A more pronounced inhibitory effect on breast cancer cell lines was observed at a DOX:SIM molar ratio of 2:1 in both free and encapsulated drugs. Furthermore, the 2:1 ratio showed synergistic combination rates for all concentrations of cell inhibition analyzed (50, 75, and 90%). The results demonstrated the promising potential of the co-encapsulated liposome for breast tumor treatment.